Lupin creates Kaveri Therapeutics to raise capital for two oncology asset clinical programs
Executive summary: Lupin transferred its oncology programs LNP7457 (PRMT5) and LNP8701 (SOS1) to a newly formed subsidiary, Kaveri Therapeutics, aiming to raise capital for global clinical studies. The spinout provides Lupin with non‑dilutive financing and lets Kaveri concentrate resources on advancing these candidates, potentially accelerating development and impacting the oncology market.
Who is involved: Lupin Limited, Kaveri Therapeutics, and investors interested in early‑stage oncology assets.
Likely next: Kaveri will initiate a fundraising round to support Phase I/II trials of LNP7457 and LNP8701, while Lupin monitors the partnership for potential milestones or further strategic moves.
Lupin Limited has spun out its PRMT5 inhibitor LNP7457 and SOS1 inhibitor LNP8701 into a new entity, Kaveri Therapeutics, to secure dedicated funding for global clinical studies. The move allows Lupin to de‑risk its oncology pipeline while providing Kaveri with a focused vehicle to advance the assets. It reflects a broader trend of large pharma using spinouts to unlock value and attract external investment.
Timeline
- — Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy (PR Newswire)
- — University of Bristol spinouts looking to raise (Sifted — EU startups)
Analysis — what this means
Sectors affected
- Oncology drug development
- Biotech drug development
- Biotech financing
Sources
- Lupin Spins Out Two Oncology Programs to Kaveri Therapeutics to Advance its Oncology Strategy — PR Newswire
- University of Bristol spinouts looking to raise — Sifted — EU startups